Reuters logo
BRIEF-Targovax granted US patent for mutant-ras neoantigen vaccines
September 25, 2017 / 5:09 AM / 2 months ago

BRIEF-Targovax granted US patent for mutant-ras neoantigen vaccines

Sept 25 (Reuters) - TARGOVAX ASA

* REG-TARGOVAX GRANTED US PATENT FOR MUTANT-RAS NEOANTIGEN PLATFORM LEAD PRODUCTS

* ‍PATENT PROTECTS TARGOVAX’ MUTANT-RAS SPECIFIC NEOANTIGEN VACCINES, TG01 AND TG02, FOR THE TREATMENT OF CANCER IN COMBINATION WITH ANTI-METABOLITE CHEMOTHERAPY

* EXTENDS IP PROTECTION OF TG01 AND TG02 UNTIL MAY 6, 2034​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below